No attachments available.
A--Drug Manufacturing and Formulation Program (DMFP)
Contact and place of performance
PLUGGE, RIEKA N
Menlo Park, CA
USA
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
The National Institutes of Health, National Institute on Drug Abuse (NIDA) awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP). These awards, identified under solicitation number 75N95024R00077, carry a maximum ordering value of $49,999,999.00 and an ordering period spanning from May 4, 2026, through May 3, 2036. Concurrent with the base awards, the agency issued the first task orders to each awardee as firm-fixed price actions totaling $5,000.00, with a performance period effective from May 4, 2026, through July 3, 2026.
This requirement is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC AN11 for Health R&D Services, Health Care Services, and Basic Research. There was no set-aside used for this procurement. Work is performed in Menlo Park, California, and the primary point of contact for the award notice is Rieka N. Plugge. No attachments were included with the published notice.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.